You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

Report to Health Ministers on a cost-benefit analysis of pharmacist only (S3) and pharmacy medicines (S2) and risk-based evaluation of the standards

25 January 2006

At its meeting on 18 November 2005, the Australian Health Ministers' Conference (AHMC) endorsed a report prepared by the National Coordinating Committee on Therapeutic Goods (NCCTG) on the results of research into A Cost-Benefit Analysis of Pharmacist Only (S3) and Pharmacy Medicines (S2) and Risk-Based Evaluation of the Standards, commissioned by the Pharmacy Guild of Australia to implement Recommendation 5 of the Review of Drugs, Poisons and Controlled Substances Legislation (the 'Galbally Review').

How to access a pdf document

The key recommendations of the NCCTG review of the research are:

  • That the scheduling model for medicines retains the Pharmacy (Schedule 2) and Pharmacist-Only (Schedule 3) schedules for non-prescription medicines for an interim period of 5 years.
  • That the Pharmacy Guild be requested to submit the summarised results of the Mystery Shopper Program to the NCCTG on a yearly basis for the next 5 years in order for the Committee to monitor any improvement in compliance with the voluntary S2/S3 standards.
  • That at the end of the 5 year period, the restrictions on access to over-the-counter medicines be reassessed in Australia and New Zealand to determine if the objectives of these restrictions are being met, taking into account relevant data, including the data gathered from the Mystery Shopper Program and an analysis of pharmacies which are not Quality Care Pharmacy Program (QCPP) accredited.
  • That the Pharmacy Guild review of the QCPP consider integrating into the S2/S3 pharmacy standards:
    • the identification of risks to consumers making a product based request; and
    • appropriate professional intervention by pharmacists to address those risks.

The NCCTG is currently liaising with the Pharmacy Guild regarding the implementation of these recommendations.